Brad H. Rovin

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

COVID-19: implications for immunosuppression in kidney disease and transplantation.

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis.

Lupus nephritis: the evolving role of novel therapeutics.

The kidney biopsy in lupus nephritis: is it still relevant?

The kidney biopsy in lupus nephritis: time to move beyond histology.

Lupus nephritis: MAINTAINing perspective in lupus nephritis trials.

Proteomics and autoimmune kidney disease.

Histologic versus clinical remission in proliferative lupus nephritis.

Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults.

Introduction: Meeting the Challenge of Lupus Nephritis.

The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future.

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.

Quiz Page February 2016: Acute Kidney Injury in a Patient With Granulomatosis With Polyangiitis Receiving Maintenance Immunosuppressive Therapy.

Hurdles to the introduction of new therapies for immune-mediated kidney diseases.

Predicting decline of kidney function in lupus nephritis using urine biomarkers.

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Current and Emerging Therapies for Lupus Nephritis.

The interleukin-6-hepcidin-hemoglobin circuit in systemic lupus erythematosus flares.

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.

Prospective validation of a novel renal activity index of lupus nephritis.

Reply.

Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise.

Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy.

Reply.

Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?

Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy.

Characterization and classification of lupus patients based on plasma thermograms.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni .

Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.

A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.

Induction Therapy for Lupus Nephritis: the Highlights.

Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.

The authors reply.

Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt .

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.

Development of a Set of Lupus-Specific Ambulatory Care Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study.

Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.

Do kidneys grow old gracefully?

Systemic autoimmune diseases and the kidney.

The authors reply.

Update on Lupus Nephritis: Core Curriculum 2020.

Kidney International and the COVID-19 infection.

Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis.

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers.